Comparative efficacy of various non-pharmacological therapies on cognitive function in patients with mild cognitive impairment or dementia: A network meta-analysis.

Medicine (Baltimore)Sep 25, 2026
Clinical ResearchGeriatricsNeurology

Hongxia Zhou, Ting Ma, Lingling Yang et al.

✦ AI-curated · Sources linked

In 30 seconds

This network meta-analysis evaluated the efficacy of non-pharmacological therapies on cognitive function in 2082 patients with mild cognitive impairment or dementia. Significant improvements in Mini-Mental State Examination scores were observed for cognitive training (SMD = 1.43) and health education (SMD = 2.02). For Montreal Cognitive Assessment scores, physical exercise (SMD = 2.26), health education (SMD = 2.43), and cognitive training (SMD = 2.96) showed significant benefits.

Key findings

  • Cognitive training improved Mini-Mental State Examination scores with an SMD of 1.43.
  • Health education showed a significant SMD of 2.02 in Mini-Mental State Examination scores.
  • Physical exercise improved Montreal Cognitive Assessment scores with an SMD of 2.26.
  • Cognitive training had the highest preliminary ranking probability for cognitive improvement.

Why it matters

Understanding the effectiveness of non-pharmacological therapies is crucial for clinicians managing patients with cognitive impairment. These findings can guide therapeutic choices to enhance cognitive function in this population.

Source

PubMed · PMID 42798077

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.